MedTrace Logo

Pulsed Electromagnetic Fields (PEMFs) - A Highly Selective Breast CAncer Treatment pLatform (PASCAL)

NCT06332508 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2026-03-13

No results posted yet for this study

Summary

To assess the safety and tolerability of combined PEMFs and anthracycline-based chemotherapy in subjects who are undergoing neoadjuvant chemotherapy for breast cancer treatment.

Conditions

Interventions

DEVICE

Pulsed electromagnetic fields (PEMFs)

A single 30-minute PEMF session to assess local toxicity.

DEVICE

Pulsed electromagnetic fields (PEMFs)

A single 30-minute PEMF session administered 30 minutes pre-surgery to assess wound-healing safety.

COMBINATION_PRODUCT

Device: Pulsed electromagnetic fields (PEMFs); Drug: Anthracycline OR Taxane

A single 30-minute PEMF session administered 30 minutes prior to the final cycle (4th cycle) of either Anthracycline (DL3a) or Taxane (DL3b) therapy.

Sponsors & Collaborators

Principal Investigators

  • Rachel Wong, Medical Degree · National University Hospital, Singapore

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
99 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-30
Primary Completion
2025-08-08
Completion
2025-08-08

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06332508 on ClinicalTrials.gov